Quantitative analysis of dopamine transporters in human brain using [ 11C]PE2I and positron emission tomography: Evaluation of reference tissue models

Annals of Nuclear Medicine

Volumn 24, Issue 4, 2010, Pages 249-260

  Seki, Chie ^a   Ito, Hiroshi ^a   Ichimiya, Tetsuya ^a   Arakawa, Ryosuke ^a   Ikoma, Yoko ^a   Shidahara, Miho ^a   Maeda, Jun ^a   Takano, Akihiro ^a   Takahashi, Hidehiko ^a   Kimura, Yuichi ^a   Suzuki, Kazutoshi ^a   Kanno, Iwao ^a   Suhara, Tetsuya ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

11CPE2I; Human; Kinetic modeling; Positron emission tomography (PET); Reference tissue model

Indexed keywords

DOPAMINE TRANSPORTER;

ADULT; ARTICLE; BRAIN REGION; COMPARTMENT MODEL; CORPUS STRIATUM; DISTRIBUTION VOLUME; HUMAN; HUMAN TISSUE; KINETICS; MALE; MESENCEPHALON; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ADULT; ARTERIES; BRAIN; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MALE; MODELS, BIOLOGICAL; NORTROPANES; POSITRON-EMISSION TOMOGRAPHY; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SYNAPSES; SYNAPTIC TRANSMISSION; TIME FACTORS; YOUNG ADULT;

EID: 77954542028     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12149-010-0364-z     Document Type: Article

References (40)

1. Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, Macgregor RR, et al. Mapping cocaine binding sites in human and baboon brain in vivo. Synapse. 1989;4(4):371-377
2. Hantraye P, Brownell AL, Elmaleh D, Spealman RD, Wullner U, Brownell GL, et al. Dopamine fiber detection by [11C]-CFT and PET in a primate model of Parkinsonism. Neuroreport. 1992;3(3):265-268
3. Wong DF, Yung B, Dannals RF, Shaya EK, Ravert HT, Chen CA, et al. In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35, 428. Synapse. 1993;15(2):130-142
4. Muller L, Halldin C, Farde L, Karlsson P, Hall H, Swahn CG, et al. [11C] beta-CIT, a cocaine analogue. Preparation, autoradiography and preliminary PET investigations. Nucl Med Biol. 1993;20(3):249-255
5. Halldin C, Farde L, Lundkvist C, Ginovart N, Nakashima Y, Karlsson P, et al. [11C]beta-CIT-FE, a radioligand for quantitation of the dopamine transporter in the living brain using positron emission tomography. Synapse. 1996;22(4):386-390
6. Ding YS, Fowler JS, Volkow ND, Gatley SJ, Logan J, Dewey SL, et al. Pharmacokinetics and in vivo specificity of [11C]DL-threomethylphenidate for the presynaptic dopaminergic neuron. Synapse. 1994;18(2):152-160
7. Goodman MM, Kilts CD, Keil R, Shi B, Martarello L, Xing D, et al. 18F-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters. Nucl Med Biol. 2000;27(1):1-12.
8. Fischman AJ, Bonab AA, Babich JW, Livni E, Alpert NM, Meltzer PC, et al. [11C, 127I] altropane: a highly selective ligand for PET imaging of dopamine transporter sites. Synapse. 2001;39(4):332-342
9. Emond P, Garreau L, Chalon S, Boazi M, Caillet M, Bricard J, et al. Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(40-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)- 2beta-carbomethoxy-3beta-(30,40-disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter. J Med Chem. 1997;40(9):1366-1372
10. Chalon S, Hall H, Saba W, Garreau L, Dolle F, Halldin C, et al. Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2beta- carbomethoxy-3beta-(40-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter. J Pharmacol Exp Ther. 2006;317(1):147-152
11. Halldin C, Erixon-Lindroth N, Pauli S, Chou YH, Okubo Y, Karlsson P, et al. [11C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. Eur J Nucl Med Mol Imaging. 2003;30(9):1220-1230
12. Leroy C, Comtat C, Trebossen R, Syrota A, Martinot JL, Ribeiro MJ. Assessment of 11C-PE2I binding to the neuronal dopamine transporter in humans with the high-spatial-resolution PET scanner HRRT. J Nucl Med. 2007;48(4):538-546
13. Prunier C, Bezard E, Montharu J, Mantzarides M, Besnard JC, Baulieu JL, et al. Presymptomatic diagnosis of experimental Parkinsonism with 123I-PE2I SPECT. Neuroimage. 2003;19(3): 810-816
14. Prunier C, Payoux P, Guilloteau D, Chalon S, Giraudeau B, Majorel C, et al. Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease. J Nucl Med. 2003;44(5):663-670
15. Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/ hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry. 2005;57(3):229-238
16. Poyot T, Conde F, Gregoire MC, Frouin V, Coulon C, Fuseau C, et al. Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and Parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa. J Cereb Blood Flow Metab. 2001;21(7):782-792
17. Arakawa R, Ichimiya T, Ito H, Takano A, Okumura M, Takahashi H, et al. Increase in thalamic binding of [11C]PE2I in patients with schizophrenia: a positron emission tomography study of dopamine transporter. J Psychiatr Res. 2009;43(15):1219-1223
18. Pinborg LH, Videbaek C, Svarer C, Yndgaard S, Paulson OB, Knudsen GM. Quantification of [123I]PE2I binding to dopamine transporters with SPET. Eur J Nucl Med Mol Imaging. 2002;29(5):623-631
19. Pinborg LH, Ziebell M, Frokjaer VG, de Nijs R, Svarer C, Haugbol S, et al. Quantification of 123I-PE2I binding to dopamine transporter with SPECT after bolus and bolus/infusion. J Nucl Med. 2005;46(7):1119-1127
20. Delorenzo C, Kumar JD, Zanderigo F, Mann JJ, Parsey RV. Modeling considerations for in vivo quantification of the dopamine transporter using [11C]PE2I and positron emission tomography. J Cereb Blood Flow Metab. 2009;29(7):1332-1345
21. Hirvonen J, Johansson J, Teras M, Oikonen V, Lumme V, Virsu P, et al. Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test-retest reproducibility. J Cereb Blood Flow Metab. 2008;28(5):1059-1069
22. Jucaite A, Odano I, Olsson H, Pauli S, Halldin C, Farde L. Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study. Eur J Nucl Med Mol Imaging. 2006;33(6):657-668
23. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4(3 Pt 1):153-158
24. Ichise M, Ballinger JR, Golan H, Vines D, Luong A, Tsai S, et al. Noninvasive quantification of dopamine D2 receptors with iodine-123-IBF SPECT. J Nucl Med. 1996;37(3):513-520
25. Huang SC, Barrio JR, Phelps ME. Neuroreceptor assay with positron emission tomography: equilibrium versus dynamic approaches. J Cereb Blood Flow Metab. 1986;6(5):515-521
26. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27(9):1533-1539
27. Mintum MA, Raichle ME, Kilbourn MR, Wooten GL, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol. 1984;15:217-227
28. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Control. 1974;19:716-723
29. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10(5):740-747
30. Hurley MJ, Mash DC, Jenner P. Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCR. Eur J Neurosci. 2003;18(9):2668-2672
31. Suzuki K, Sasaki M, Kubodera A. Approach to ultra high specific activity for 11C-labeled compounds. Synthesis of [11C]FLB 457 and [11C]Ro-15-4513. J Labelled Comp Radiopharm. 1999;42: S129-31.
32. Suzuki K, Inoue O, Tamate K, Mikado F. Production of 3-N-[11C] methylspiperone with high specific activity and high radiochemical purity for PET studies: suppression of its radiolysis. Int J Rad Appl Instrum A. 1990;41(6):593-599
33. Brix G, Zaers J, LE Adam, Bellemann ME, Ostertag H, Trojan H, et al. Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med. 1997;38(10):1614-1623
34. Eriksson L, Holte S, Bohm C, Kesselberg M, Hovander B. Automated blood sampling system for positron emission tomography. IEEE Trans Nucl Sci. 1988;35:703-707
35. Friston KJ, Holmes AP, Poline JB, Grasby PJ, Williams SC, Frackowiak RS, et al. Analysis of fMRI time-series revisited. Neuroimage. 1995;2(1):45-53.
36. Hall H, Halldin C, Guilloteau D, Chalon S, Emond P, Besnard J, et al. Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [125I]PE2I. Neuroimage. 1999;9(1):108-116
37. Shetty HU, Zoghbi SS, Liow JS, Ichise M, Hong J, Musachio JL, et al. Identification and regional distribution in rat brain of radiometabolites of the dopamine transporter PET radioligand [11C]PE2I. Eur J Nucl Med Mol Imaging. 2007;34(5):667-678
38. Slifstein M, Laruelle M. Effects of statistical noise on graphic analysis of PET neuroreceptor studies. J Nucl Med. 2000;41(12): 2083-2088
39. Parsey RV, Slifstein M, Hwang DR, Abi-Dargham A, Simpson N, Mawlawi O, et al. Validation and reproducibility of measurement of 5-HT1A receptor parameters with [carbonyl-11C]WAY-100635 in humans: comparison of arterial and reference tissue input functions. J Cereb Blood Flow Metab. 2000;20(7):1111-1133
40. Ichise M, Liow JS, Lu JQ, Takano A, Model K, Toyama H, et al. Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab. 2003;23(9):1096-1112